NeoGenomics, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Anthony Zook
- Full Time Employees
- 2,500
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- 9490 NeoGenomics Way Fort Myers FL United States of America 33912
- IPO Date
- Mar 16, 2004
- CIK
- 0001077183
- Website
- neogenomics.com
- Similar Companies
- Business
- NeoGenomics, Inc. is a cancer diagnostics company specializing in cancer genetics testing and information services. The company offers an extensive oncology-focused testing menu across multiple modalities, including clinical cancer testing; molecular and next-generation sequencing (NGS) testing; interpretation and consultative services; validation laboratory services; clinical trials and research testing; and oncology data solutions. NeoGenomics serves a broad customer base comprising pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations primarily across the United States and Europe. Its laboratories are CAP accredited and CLIA certified and are located in multiple sites including Fort Myers and Tampa in Florida; California locations such as Aliso Viejo, Carlsbad, and San Diego; Research Triangle Park, North Carolina; Houston, Texas; Atlanta, Georgia; Nashville, Tennessee; Phoenix, Arizona; and Cambridge, United Kingdom. Founded in 2002 and headquartered in Fort Myers, Florida, NeoGenomics operates as a leader in precision oncology diagnostics offering over 500 advanced tests for personalized cancer care. Recent major developments include the completion of the acquisition of Pathline, LLC, a CLIA/CAP/NYS-certified laboratory based in New Jersey, which expands NeoGenomics' oncology testing reach and service capabilities in the Northeast U.S. The company has also formed a global strategic partnership with Biognosys AG to enhance its proteomics-based product offerings for its Pharma Services division, expanding into next-generation proteomics solutions for drug discovery and clinical trials in oncology drug development. Additionally, NeoGenomics has launched NEO PanTracer LBx, a blood-based comprehensive genomic profiling liquid biopsy test, advancing its position in the precision oncology market by offering less invasive and faster genomic testing options for therapy selection, trial matching, and disease monitoring. NeoGenomics is further strengthening its portfolio with several new next-generation sequencing products in late-stage development, scheduled for launch to bolster its presence in hospitals and community oncology settings. These strategic expansions and product innovations underscore the company's commitment to clinical leadership and sustainable growth in the cancer diagnostics and research market. NeoGenomics reported consolidated revenue of approximately $661 million for 2024, reflecting a 12% increase driven by higher test volumes. NeoGenomics operates within the healthcare diagnostics and research industry, targeting oncology-focused markets with advanced genetic and molecular testing services. It supports oncology clinical care and pharma research globally, with notable operations in the U.S. and the UK, and its strategic initiatives continue to broaden its capabilities in precision medicine and oncology data analytics. The company employs around 2,200 professionals and is led by CEO Anthony P. Zook. Its ongoing commitment to innovation and strategic acquisitions positions it as a prominent player in cancer genetics testing and oncology contract research service provider spaces.
Which Is the Better Healthcare ETF: First Trust's High-Conviction FBT or Vanguard's Low-Cost VHT?
Which Is the Better Healthcare ETF, First Trust's Biotech-Focused FBT or State Street's Broader XLV?
NeoGenomics Announces Settlement of Voluntary Disclosure to OIG-HHS
NeOnc Receives FDA Written Feedback on NEO212 CMC Development and Capsule-to-Tablet Transition
NeoGenomics Launches FDA-Approved PTEN IHC Companion Diagnostic for Prostate Cancer
NeoGenomics to Report Second Quarter 2026 Financial Results on July 28, 2026
NeoGenomics Appoints Carolyn Starrett to its Board of Directors
NeOnc Technologies Receives UAE IND Approval for NEO100, Expanding Global Development Ahead of Anticipated Phase 2 Data Milestone
NeoGenomics (NEO) Soars 7.2%: Is Further Upside Left in the Stock?
Neo Performance Materials Inc. (NEO:CA) Shareholder/Analyst Call Prepared Remarks Transcript
NeoGenomics Announces Pricing of Offering of $275 Million Convertible Senior Notes
Employers Tighten Focus on AI and Human Skills as Global Tech Hiring Moderates
NeOnc Technologies Secures UAE IND Approval for NEO212 Following Successful Phase 1 Completion, Advancing Toward Global Phase 2 Development
NeoGenomics Announces Proposed Offering of $275 Million Convertible Senior Notes
NeoGenomics Inc (NEO) Stock Up 6.5% and Still Undervalued -- GF Score: 68/100
Neo Performance Materials Announces C$100 Million Bought Deal Treasury Offering of Common Shares
Neo Partners with Greenland Mines to Advance Sarfartoq Rare Earth Project
NeoGenomics to Participate in Upcoming Investor Conferences
NeoGenomics to Participate in Upcoming Investor Conferences
Neo Performance Materials Inc. (NEO:CA) Q1 2026 Earnings Call Transcript